NEJM reports on randomized trial of Ruxolitinib vs phlebotomy in Hydroxyurea-resistant PV

January 29, 2015

The New England Journal of Medicine has just published a paper co-authored by Claire N. Harrison, D.M., Ruben Mesa, M.D. and Srdan Verstovsek, M.D., Ph.D. among others, describing the outcome of a trial measuring Ruxolitinb in polycythemia vera patients who are intolerant or who do not respond to Hydroxyurea. Patients were randomly assigned either Ruxolitinib or phlebotomy treatment for this trial. The results suggested that patients had better hematocrit control and reduced spleen size on Ruxolitinib versus phlebotomy. Read the full article:

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.



Get free, timely information on living with an MPN.